A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE005 (FRA) · Dr. Muller
consented 2023-01-05
AEs
4
Serious
1
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-01-19 (study day 7); relationship: N
severe
serious
assessed
Grade 3 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-02-02 (study day 21); relationship: Y; serious criteria: hospitalization
mild
assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-03-31 (study day 78); relationship: N
mild
assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-06-21 (study day 160); relationship: not assessed
Data queries
No data queries.